🕒 Last update: loading…22/11/2026

Stock American Oriental Bioengineering, Inc. AOBI

American Oriental Bioengineering, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 371.70%

Price change 2019 → 2020: -99.89%

Price change 2020 → 2021: -92.73%

Price change 2021 → 2022: 0.00%

Price change 2022 → 2023: 150.00%

Price change 2023 → 2024: 0.00%

Price change 2024 → 2025: 140.00%

Price change 2025 → 2026: 983.33%

Price change 2026 (year to date): 983.33%

Financial growth

Revenue CAGR (8 years): 14.94%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.21

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio not available.

Correction (6 months)

Current correction: 0.00% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by American Oriental Bioengineering, Inc. over the latest fiscal years.

Revenue
145 m USD
fiscal year 2012
Net income
-59.7 m USD
fiscal year 2012
Net margin
-41.1 %
fiscal year 2012
Market cap
949 USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2010306 m14.1 m4.6 %n/a
2011213 m-68.5 m-32.2 %-30.5 %
2012145 m-59.7 m-41.1 %-31.8 %

Amounts converted to USD. Source: published annual accounts, collected on 20/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by American Oriental Bioengineering, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-0.46
risk zone (below 1.81)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-1.53 x
net cash

Trailing 12-month ratios

Return on Equity (ROE)-16.8 %
Return on Invested Capital (ROIC)-13.9 %
Net margin-41.1 %
Debt / equity0.21 x
Current ratio0.90 x
Interest coverage-9.42 x

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 21/11/2026.

+

Valuation and competitors

American Oriental Bioengineering, Inc. compared with its sector on the same exchange and with its main competitors.

Direct competitors

CompanyMarket cap (USD)P/ENet margin
American Oriental Bioengineering, Inc.949n/an/a
Cardax, Inc. CDXI80n/an/a
Nobilis Health Corp. NRTSF78n/an/a
Mymetics Corporation MYMX46n/an/a
NexImmune, Inc. NEXI139n/an/a
Cannabiz Mobile, Inc. LGBI505n/an/a
Sector 10, Inc. SECI31n/an/a
Poniard Pharmaceuticals, Inc. PARD150n/an/a

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 20/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

American Oriental Bioengineering, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Stock splits

DateOperation
21/08/2014reverse split: 1 share for 501
03/04/2014reverse split: 1 share for 501
27/02/2012reverse split: 1 share for 2

Factual data: ex-dividend history and earnings calendar, as of 21/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in American Oriental Bioengineering, Inc.

Free float
77.1 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 21/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
OTC (hors cote)
IPO: 12/12/2001
ISIN code
US0287315032
Workforce
3,719
full-time employees
Chief executive
Shujun Liu

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about American Oriental Bioengineering, Inc.

What is the American Oriental Bioengineering, Inc. share price?

Latest recorded price: 0.0130 USD on 20/11/2026, for a market cap of 949 USD.

What is the revenue of American Oriental Bioengineering, Inc.?

145 m USD for fiscal year 2012, with net income of -59.7 m USD (net margin -41.1 %).

Is American Oriental Bioengineering, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US0287315032).

How many employees does American Oriental Bioengineering, Inc. have?

3,719 full-time employees according to the latest published profile.

Who runs American Oriental Bioengineering, Inc.?

Shujun Liu is the company's chief executive.